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Abstract
Background: Retinopathy of Prematurity (ROP) is a common retinal neovascular disorder of premature infants.
It is of variable severity, usually heals with mild or no sequelae, but may progress to blindness from retinal
detachments or severe retinal scar formation. This is a preliminary report of the effectiveness and safety of a new
and original use of topical ketorolac in preterm newborn to prevent the progression of ROP to the more severe
forms of this disease.
Methods: From January 2001 to December 2002, all fifty nine preterm newborns with birthweight less than 1250
grams or gestational age less than 30 weeks of gestational age admitted to neonatal intensive care were eligible
for treatment with topical ketorolac (0.25 milligrams every 8 hours in each eye). The historical comparison group
included all 53 preterm newborns, with the same inclusion criteria, admitted between January 1999 and
December 2000.
Results: Groups were comparable in terms of weight distribution, Apgar score at 5 minutes, incidence of sepsis,
intraventricular hemorrhage and necrotizing enterocolitis. The duration of oxygen therapy was significantly longer
in the control group. In the ketorolac group, among 43 children that were alive at discharge, one (2.3%) developed
threshold ROP and cryotherapy was necessary. In the comparison group 35 children survived, and six child (17%)
needed cryotherapy (Relative Risk 0.14, 95%CI 0.00 to 0.80, p = 0.041). Adjusting by duration of oxygen therapy
did not significantly change these results. Adverse effects attributable to ketorolac were not detected.
Conclusions: This preliminary report suggests that ketorolac in the form of an ophthalmic solution can reduce
the risk of developing severe ROP in very preterm newborns, without producing significant adverse side effects.
These results, although promising, should be interpreted with caution because of the weakness of the study
design. This is an inexpensive and simple intervention that might ameliorate the progression of a disease with
devastating consequences for children and their families. We believe that next logical step would be to assess the
effectiveness of this intervention in a randomized controlled trial of adequate sample size.
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Background
Retinopathy of Prematurity (ROP) is a common retinal
neovascular disorder of premature infants. It is of variable
severity, usually heals with mild or no sequelae, but may
progress in some infants to partial vision loss or blindness
from retinal detachments or severe retinal scar formation
[1]. ROP remains as one of the most frequent cause of
blindness in children, in particular in countries with
infant mortality rates between 10 and 60/1000 [2,3].
Among 177 students attending schools for children with
visual impairment in the city were this study was con-
ducted, 107 (60.5%) had ROP [4]. The incidence of both
any acute ROP, and of the more severe stages, varies
inversely with gestational age at birth. ROP is unusual
(except in the mildest forms) in infants of greater than 31
weeks gestation, and severe complications such as retinal
detachment occur in less than one half of one percent of
infants greater than 31 weeks gestation. However, more
than 80% of infants less than 28 weeks gestation develop
some ROP, and around 10% develop "threshold ROP. In
threshold ROP more that 40% of the cases progresses to
retina folds or detachment, with its consequent blindness.
In this stage, ablative surgery (cryotherapy or laser photo-
coagulation) to the peripheral avascular retina is recom-
mended to reduce the risk of disease progression to retinal
detachment [5-7]. Pre-threshold stage has been linked to
bad results in the visual function: reduction of visual acu-
ity, short-sightedness, amblyopic, etc. [8,9]. A number of
strategies have been developed to try to diminish the
progress of ROP, but with limited success. These strategies
include antioxidants such as vitamin E [10], D penicilla-
mine [11] and allopurinol [12], reduction of exposure to
light [13] and supplementation with oxygen [14].
The active disease appears in the premature about 4 to 8
weeks after birth. In this period, the levels of vascular
endothelial growth factor (VEGF) increase in the retina, as
well as other chemical mediators of inflammation such as
platelets activator factor (PAF), prostaglandins (PGs), and
eicosanoids which would put again under way the process
of vascularization that had stopped in the period of oxida-
tive injury. This vascularization is now degenerated and
invasive [15-17].
In models of animal experimentation it was possible to
diminish the degree of retinal neovascularization with use
of indometacin [18], dexamethasone [19], rofecoxib [20],
and bucillamine [21], and increased activity of cyclooxy-
genase 2 (COX2) was also demonstrated in vessels of neo-
proliferation in retina and its inhibition decreases the
neovascularization in 37% [20].
Ketorolac is a non-steroid anti-inflammatory drug
(NSAID) derived from indometacin. Its mechanism of
action is developed through the interruption of the syn-
thesis of prostanoids, inhibiting the way of COX 1 and 2
in arachidonic acid metabolism; in this way the tissue lev-
els of prostaglandin F2alfa and thromboxane B2 decrease.
Its adverse effects are linked predominantly to their inhib-
itory action of platelet aggregation. It does not alter either
the platelet count, or factors of clotting. High digestive
hemorrhage is the principal adverse reaction. Nervous
and cardiovascular systems are not generally affected by
the use of ketorolac to habitual doses [22-24].
Ketorolac administered as conjunctival topical diminishes
prostaglandin E2 concentration in aqueous humor, with-
out modifying the intraocular pressure [24]. In addition it
is effective in uveitis induced by tumors necrosis factor
(TNF) [25]. Ketorolac is unquantifiable in plasma when
administered in ophthalmic drops [24].
Ketorolac ophthalmic solution is usually used in older
adults with retinal disorders. It is used to diminish the
Cystoid Macular Edema that complicates the surgery of
cataracts. In this pathology ketorolac has proved to be
effective in diminishing the macular edema and improv-
ing the visual acuity, providing evidence that their con-
junctival instillation produce effects on the most internal
layers of the eye. The ophthalmic use of ketorolac only
reports occasional episodes of discomfort and ocular
burning [26-28].
The use of ketorolac ophthalmic solution in pediatrics is
frequent as an analgesic in corneal abrasions, and in aller-
gic and post surgical conjunctivitis. The FDA recognizes its
indication for allergic conjunctivitis, ocular pain, post sur-
gical ocular inflammation, ocular pruritus and photopho-
bia [24,29].
On the basis of experimental evidence and physio-patho-
genic rationality, we treated preterm newborns admitted
to neonatal intensive care unit (NICU) of our hospital
with ketorolac in ophthalmic drops with the aim of
decreasing the progression and severity of ROP. This study
compares this group of children treated with ketorolac
with historic controls to assess the impact of this treat-
ment on the incidence of severe ROP and adverse effects.
Methods
This is a preliminary report, that compares a cohort of
children treated with ketorolac with historic controls that
did not received such treatment. From January 2001 to
December 2002 all preterm newborns with birthweight
less than 1250 g or gestational age less than 30 weeks of
gestational age, admitted in the NICU of the University
Hospital of Maternity and Neonatology of the city of Cór-
doba, Argentina, were eligible for treatment with topical
ketorolac. The comparison group included all preterm
newborns, with the same inclusion criteria, admittedBMC Pediatrics 2004, 4:15 http://www.biomedcentral.com/1471-2431/4/15
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between January 1999 and December 2000. None of these
newborns received treatment with ketorolac.
There were no differences either in treatment guidelines,
equipment or in the number of physicians and nurses that
took care of the patients in the two periods. All the chil-
dren were examined by the same group of ophthalmolo-
gists, which have many years of experience in treating
patients with ROP. The international classification for
ROP [30] was used to define the stages of the disease and
verified by more than one observer.
During the period in which ketorolac tromethamine was
used, when risk signs for ROP were identified (zone I
incomplete vascularization, vessels only in zone of transi-
tion I-II or anomalous ramification and equatorial incur-
vation of vessels in the avascular – vascular junction) [31]
treatment was started with a drop of ketorolac trometh-
amine (0.25 mgrs.) every 8 hours in each eye. The treat-
ment continued until they presented signs of threshold
ROP and cryotherapy was indicated, or till the resolution
of the condition. Parents of these children gave their con-
sent so that their children could receive treatment.
The variables considered to assess the comparability
among both groups were: birthweight, Apgar score at
birth less than 6 at 5 minutes, duration of oxygen therapy,
peri-intraventricular hemorrhage (PIVH) equal or greater
than 3 degrees, necrotizing enterocolitis (NEC) equal of
greater than II degrees, and late sepsis. The analyses
included only those children that were alive at discharge,
but the number of deaths was reported for both study
periods. The presence of undesirable effects of ketorolac
such as hemorrhages, oliguresis, local manifestations of
intolerance, and conjunctival infection were analyzed.
Fischer exact test was used to obtain two tailed p-values.
Relative risks (RR) with 95% confidence intervals where
also calculated. Adjusted analyses were performed by
using Poisson regression with robust estimates [32]. Sta-
tistical analysis was carried out using the statistical soft-
ware SPSS version 8.0, Stats Direct, and STATA version
8.0.
Results
During the analyzed period 112 eligible preterm new-
borns were admitted, 53 between 1999 and 2000 (historic
controls) and 59 between 2001 and 2002 (ketorolac
group). The number of newborns that died before dis-
charge was similar between groups (see table 1). Table 1
presents the characteristic of those alive at discharge.
Groups were comparable in terms of weight distribution,
Apgar score at 5 minutes, incidence of sepsis, intraven-
tricular hemorrhage and necrotizing Enterocolitis (see
table 1). The duration of oxygen therapy was significantly
longer in the control group (see table 1).
In the ketorolac group 45 children were alive at the first
ophthalmic control, two died before discharge due to late
sepsis, so 43 received treatment with ketorolac. Nineteen
children were discharged from NICU with treatment
indication, and continued with ketorolac up to 44 weeks
of gestational age, when the ophthalmologists considered
that the risk for developing ROP was very small.
Table 1: Characteristics of newborns treated with ketorolac and historic controls.
Historic controls Ketorolac p**
Year 1999 – 2000 Year 2001–2002
N = 35† N = 43†
n(%) n(%)
Dead before discharge* 18 (34.0) 16 (27.1) 0.54
Birthweight (g) 0.28
<= 750 4 (11.4) 8 (18.6)
751–1000 13 (37.1) 9 (20.9)
1001–1250 18 (51.4) 26 (60.59
Apgar Score < 6 at 5 minutes 10 (28.6) 11 (25.5) 0.80
Oxygen (days) 0.01
0–10 9 (25.7) 21 (48.8)
11–27 10 (28.6) 15 (34.9)
>= 28 16 (45.7) 7 (16.3)
Sepsis 16 (45.7) 24 (55.8) 0.50
Peri–intraventricular hemorrhage > grade III 8 (22.9) 6 (14.0) 0.38
Necrotizing Enterocolitis >= II degree 5 (14.3) 9 (20.9) 0.56
† Excludes newborns that died before discharge. * N = 53 in historic controls group and N = 59 in ketorolac group, that includes all eligible live 
newborn during the study period. ** P-value Fisher exact test.BMC Pediatrics 2004, 4:15 http://www.biomedcentral.com/1471-2431/4/15
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The incidence of threshold ROP in newborns treated with
ketorolac was significantly lower (Relative Risk Reduction
86%) than in the control group (see table 2). Adjusting for
duration of oxygen therapy did not significantly change
these results (see table 2). Further exploration of this rela-
tionship showed that duration of oxygen therapy equal or
higher than 28 days was not associated with severe ROP in
this data (Relative Risk 1.04, 95%CI 0.25 to 4.51, p =
0.28). This finding explains why duration of oxygen ther-
apy does not act as a confounder. Hemorrhages were not
observed in the vitreous after treatment with ketorolac. In
four cases hemorrhages in the vitreous were already
present at the beginning of therapy and they disappeared
after 14 days of treatment. No signs of local intolerance,
or conjunctival infection were observed. We did not find
hemorrhages in other organs attributable to the drug, or
signs of renal failure. Treatment was not suspended in
none of the cases and all preterm babies received ketoro-
lac until its interruption due to the resolution of ROP or
the indication of cryotherapy.
Discussion
In this preliminary study we have shown that the inci-
dence of severe ROP was significantly lower in very pre-
term newborns treated with ketorolac, compared with
historic controls not receiving such treatment. These
results suggest that administration of ketorolac as an oph-
thalmic solution might be an effective preventive strategy
in patient at risk of developing severe ROP. The study was
conducted on non-concurrent patient groups, and
changes in the subjects risk profile or quality of care
between the two study periods might have an impact in
the risk of developing severe ROP. The magnitude of the
effect of ketorolac on the incidence of severe ROP found
in this study (from 17% in the control group to 2.3% in
the ketorolac group) is large and in our opinion unlikely
to be explained completely by confounding factors,
although this possibility cannot be completely ruled out.
To our knowledge, no significant change in the standard
of care took place between the study periods, but mortal-
ity was lower during the period were ketorolac was used,
although the difference was not statistically significant.
The groups were comparable in terms of their birthweight
distribution, Apgar score, and indicators of severe mor-
bidity. A significant difference was found in duration of
oxygen therapy, but in our data there was no association
between duration of oxygen therapy and severe ROP, and
adjusting for oxygen did not change the results. The prin-
cipal factor involved in the genesis and severity of ROP is
the injury due to O2 radicals; there were no substantial
changes in the management of O2 supply to the children
of our unit in both periods, the equipment used to meas-
ured O2 saturation and to administer the oxygen.
The prevalence of severe ROP in our maternity was rela-
tively high, considering that for 1998 the Vermont-Oxford
Network reported an incidence of 9.5% for severe ROP
and of 57.2% for ROP of any degree [33], but similar to
the one reported by other units in our country and in oth-
ers countries with similar development [34-36]
Ketorolac was apparently safe. No patients in the group
that received ketorolac presented oliguric, or with bio-
chemical signs of renal failure during treatment. There
were no hemorrhagic manifestations that could be attrib-
uted to ketorolac; hemorrhages observed in vitreous
evolved favorably with collyrium. Neither local intoler-
ance episodes to the drops nor purulent conjunctivitis
among the treated cases were observed.
The effect on ROP we have observed is compatible with an
impact of Ketorolac in the active phase of neovasculariza-
tion, a fact that is also observed in numerous reports in
animal models of ROP with NSAIDs and steroid drugs
administered systemically. The hypothesis of an inflam-
matory component in active ROP has been quite recently
recognized by experts, extensive leukocyte adhesion was
observed at the leading edge of pathological
neovascularization [17]. Recent research work with inhib-
itors of COX2 shows that anti-inflammatory drugs appar-
ently have an impact on the evolution of ROP [20].
Neufeld and collaborators found high plasmatic profiles
of TNF and other cytokines during the phase of installa-
tion of the pre-threshold stage for ROP [37]. COX has a
strong angiogenic action in the normal development of
retina. The inhibition of COX2 diminishes the angiogen-
esis in cancer and rheumatoid arthritis [38]. The ganglion
cells of retina secrete PGs that would interact with ang-
Table 2: Incidence of threshold retinopathy of prematurity in newborns treated with ketorolac and historic controls. Only those alive 
at discharged included in the analyses.
Historic Controls Ketorolac Relative Risk (95%CI) P-value
n/N(%) n/N(%) Crude Adjusted*
Threshold retinopathy 
of prematurity
6/35 (17.1) 1/43 (2.3) 0.14 (0.00 to 0.80) 0.041** 0.12 (0.02 to 0.92) 0.04
* Adjusted by oxygen administration using robust Poisson Regression. **Fisher exact testBMC Pediatrics 2004, 4:15 http://www.biomedcentral.com/1471-2431/4/15
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iogenic substances as VEGF and Insulin like growth factor.
The neo-vessels express a greater concentration of COX2
and inhibitors of COX2 stop the angiogenesis mediated
by VEFG, which is the principal factor involved in the neo-
vascularization and which would be regulated by the PGs
secreted by ganglion cells of retina and endothelial cells
[20]. The hyperoxia induces liberation of TNF with a pow-
erful inflammatory action; dexamethasone interferes with
TNF production attenuating the manifestations of retin-
opathy by hyperoxia [19]. Topical ketorolac is very effec-
tive in neutralizing uveitis generated by experimental
infection with monoclonal TNF or bacterial endotoxins
[25,39,40].
ROP is a problem that modern medicine has generated
due to the survival of very small preterm children and
which has been unable to solve so far. About 2% of the
children with birthweight less than 1500 grams are blind
because of this pathology. Current preventive interven-
tions can prevent blindness in nearly 70% of the cases.
Earlier treatment using ablation of the avascular retina in
pre-threshold ROP has been proposed [41], but a preven-
tive measure that could avoid the need of ablation would
be much better.
Conclusions
This preliminary report provides evidence suggesting that
ketorolac in the form of an ophthalmic solution can be
used to reduce the risk of developing severe ROP in very
preterm newborns, without producing significant adverse
side effects. These results, although promising, should be
interpreted with caution because of the weakness of the
study design. We cannot exclude the possibility of bias
been responsible of the observed effect. On the other
hand, if confirmed, these results can have important pub-
lic health implications. This is an inexpensive and simple
intervention that might ameliorate the progression of a
disease with devastating consequences for children and
their families. We believe that next logical step would be
to assess the effectiveness of this intervention in a rand-
omized controlled trial of adequate sample size to provide
a definite answer to this research question.
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